Marsden C A, Tyrer P, Casey P, Seivewright N
Department of Physiology and Pharmacology, Medical School, Queen's Medical Centre, Nottingham NG7 2UH, UK.
J Psychopharmacol. 1987 Jan;1(4):244-50. doi: 10.1177/026988118700100405.
The effects of the specific 5-hydroxytryptamine (5-HT) reuptake inhibitor parox etine on whole blood 5-HT and the uptake of (3)H-5-HT by platelets was determined in 17 patients with resistant depression. The biochemical parameters were measured before paroxetine treatment, during treatment and after withdrawal of treatment. Two of the 17 subjects failed to complete the trial; of the remaining subjects 12 showed a marked decrease in whole blood 5-HT and (3)H-5-HT uptake into platelets. The remaining three patients showed a variable response both in terms of whole blood 5-HT and platelet uptake during paroxetine treatment. At the end of treatment blood 5-HT tended to return towards normal although this was delayed. There was no significant correlation between the change in blood 5-HT and Hamilton score during paroxetine treatment. The results confirm that inhibition of 5-HT uptake mech anisms are associated with decreased whole blood 5-HT but that changes in whole blood 5- HT do not necessarily reflect the clinical efficacy of 5-HT uptake blocking drugs in the treatment of depression.
在17例难治性抑郁症患者中,测定了特异性5-羟色胺(5-HT)再摄取抑制剂帕罗西汀对全血5-HT及血小板摄取(3)H-5-HT的影响。在帕罗西汀治疗前、治疗期间及停药后测量生化参数。17名受试者中有2名未完成试验;其余受试者中,12名全血5-HT及血小板摄取(3)H-5-HT显著降低。其余3名患者在帕罗西汀治疗期间全血5-HT和血小板摄取方面表现出不同的反应。治疗结束时,血液5-HT虽有延迟但趋于恢复正常。帕罗西汀治疗期间血液5-HT的变化与汉密尔顿评分之间无显著相关性。结果证实,5-HT摄取机制的抑制与全血5-HT降低有关,但全血5-HT的变化不一定反映5-HT摄取阻断药物治疗抑郁症的临床疗效。